Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Denali Therapeutics (DNLI) Receivables - Other (2017 - 2022)

Denali Therapeutics (DNLI) has disclosed Receivables - Other for 5 consecutive years, with $357000.0 as the latest value for Q2 2022.

  • On a quarterly basis, Receivables - Other fell 77.22% to $357000.0 in Q2 2022 year-over-year; TTM through Jun 2022 was $357000.0, a 77.22% decrease, with the full-year FY2021 number at $1.2 million, down 78.39% from a year prior.
  • Receivables - Other was $357000.0 for Q2 2022 at Denali Therapeutics, down from $1.2 million in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $5.7 million in Q4 2020 to a low of $357000.0 in Q2 2022.
  • A 4-year average of $2.0 million and a median of $1.2 million in 2021 define the central range for Receivables - Other.
  • Peak YoY movement for Receivables - Other: skyrocketed 154.74% in 2018, then crashed 78.39% in 2021.
  • Denali Therapeutics' Receivables - Other stood at $1.2 million in 2018, then surged by 380.03% to $5.7 million in 2020, then plummeted by 78.39% to $1.2 million in 2021, then plummeted by 70.88% to $357000.0 in 2022.
  • Per Business Quant, the three most recent readings for DNLI's Receivables - Other are $357000.0 (Q2 2022), $1.2 million (Q4 2021), and $1.2 million (Q3 2021).